Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREDICT in Prostate Cancer
NCT06632977Phase 2Recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Feb 2025
- Primary completion
- Apr 2030
- Modality
- DNA Intercalators/Alkylators, Lipid-based Nanoparticles, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label trial of valemetostat, carboplatin and cabazitaxel ginsenoside liposome injection in castration-resistant prostate cancer (CRPC) (3 arms), sponsored by Cancer and Leukemia Group B. Primary endpoint: Objective Response Rate at 6 months. Started Feb 2025; status: recruiting.
02
Drugs
valemetostatcarboplatincabazitaxel ginsenoside liposome injection
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT06632977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06632977.